Buprenorphine–naloxone (bup/nal in 4: 1 ratio; Suboxone®; Reckitt Benckiser
Pharmaceuticals Incorporation, Richmond, VA) is approved by the Food and Drug …

Background: Sublingual buprenorphine-naloxone (buprenorphine SL) is a preparation that
is used to treat opioid dependence. In addition, the Drug Enforcement Administration (DEA) …

Objective An expert panel convened to reach a consensus on common misconceptions
surrounding buprenorphine, a Schedule III partial µ-opioid receptor agonist indicated for …

Background: Starting with approval for clinical use in the treatment of opioid dependence in
October 2002 by the Food and Drug Administration (FDA), buprenorphine has become an …

Objective Sublingual buprenorphine/naloxone (Bup/Nx) is approved for addiction treatment
and may be useful for pain management, particularly in opioid-treated pain patients with …

Buprenorphine has been in clinical use in anaesthesia for several decades. Recently, the
high-dose sublingual formulation (Subutex®, Reckitt Benckiser, Slough, UK) has been …

New effective analgesics are needed for the treatment of pain. Buprenorphine, a partial mu-
opioid agonist which has been in clinical use for over 25 years, has been found to be …

The buprenorphine receptor binding profile is unique in that it binds to all three major opioid
receptors (mu, kappa, delta), and also binds to the orphan-like receptor, the receptor for …

Interest in the use of buprenorphine as an analgesic has increased in recent years. Its
unique agonist-antagonist properties makes it a useful analgesic with a potential lower …

The analgesic potential of buprenorphine, a high-affinity partial m agonist, has been a
subject of study for several decades. The drug is now widely recognized as being extremely …